United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - busulfan - solution for infusion - 6mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - vinorelbine tartrate - oral capsule - 20mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - vinorelbine tartrate - oral capsule - 30mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - clobetasol propionate - cutaneous foam - 500microgram/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre dermo-cosmetique - metronidazole - cutaneous cream - 7.5mg/1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - vinorelbine tartrate - oral capsule - 80mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - vinflunine ditartrate - solution for infusion - 25mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pierre fabre ltd - vinflunine ditartrate - solution for infusion - 25mg/1ml

European Union - English - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastic agents - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy

European Union - English - EMA (European Medicines Agency)

pierre fabre medicament - binimetinib - melanoma - antineoplastic agents - binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.